Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development

Caroline Aspord, Alexander Pedroza-Gonzalez, Mike Gallegos, Sasha Tindle, Elizabeth C. Burton, Dan Su, Florentina Marches, Jacques Banchereau, A. Karolina Palucka

Research output: Contribution to journalArticle

Abstract

We previously reported (Bell, D., P. Chomarat, D. Broyles, G. Netto, G.M. Harb, S. Lebecque, J. Valladeau, J. Davoust, K.A. Palucka, and J. Banchereau. 1999. J. Exp. Med. 190: 1417-1426) that breast cancer tumors are infiltrated with mature dendritic cells (DCs), which cluster with CD4+ T cells. We now show that CD4+ T cells infiltrating breast cancer tumors secrete type 1 (interferon γ) as well as high levels of type 2 (interleukin [IL] 4 and IL-13) cytokines. Immunofluorescence staining of tissue sections revealed intense IL-13 staining on breast cancer cells. The expression of phosphorylated signal transducer and activator of transcription 6 in breast cancer cells suggests that IL-13 actually delivers signals to cancer cells. To determine the link between breast cancer, DCs, and CD4+ T cells, we implanted human breast cancer cell lines in nonobese diabetic/LtSz-scid/scid β2 microglobulin-deficient mice engrafted with human CD34+ hematopoietic progenitor cells and autologous T cells. There, CD4+ T cells promote early tumor development. This is dependent on DCs and can be partially prevented by administration of IL-13 antagonists. Thus, breast cancer targets DCs to facilitate its development. JEM

Original languageEnglish (US)
Pages (from-to)1037-1047
Number of pages11
JournalJournal of Experimental Medicine
Volume204
Issue number5
DOIs
StatePublished - May 2007
Externally publishedYes

Fingerprint

Interleukin-13
Dendritic Cells
Breast Neoplasms
T-Lymphocytes
Neoplasms
STAT6 Transcription Factor
Staining and Labeling
Interferon Type I
Hematopoietic Stem Cells
Interleukin-4
Fluorescent Antibody Technique
Cytokines
Cell Line

ASJC Scopus subject areas

  • Immunology

Cite this

Aspord, C., Pedroza-Gonzalez, A., Gallegos, M., Tindle, S., Burton, E. C., Su, D., ... Palucka, A. K. (2007). Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. Journal of Experimental Medicine, 204(5), 1037-1047. https://doi.org/10.1084/jem.20061120

Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. / Aspord, Caroline; Pedroza-Gonzalez, Alexander; Gallegos, Mike; Tindle, Sasha; Burton, Elizabeth C.; Su, Dan; Marches, Florentina; Banchereau, Jacques; Palucka, A. Karolina.

In: Journal of Experimental Medicine, Vol. 204, No. 5, 05.2007, p. 1037-1047.

Research output: Contribution to journalArticle

Aspord, C, Pedroza-Gonzalez, A, Gallegos, M, Tindle, S, Burton, EC, Su, D, Marches, F, Banchereau, J & Palucka, AK 2007, 'Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development', Journal of Experimental Medicine, vol. 204, no. 5, pp. 1037-1047. https://doi.org/10.1084/jem.20061120
Aspord, Caroline ; Pedroza-Gonzalez, Alexander ; Gallegos, Mike ; Tindle, Sasha ; Burton, Elizabeth C. ; Su, Dan ; Marches, Florentina ; Banchereau, Jacques ; Palucka, A. Karolina. / Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. In: Journal of Experimental Medicine. 2007 ; Vol. 204, No. 5. pp. 1037-1047.
@article{890cd8be34104af59e75674f35662a82,
title = "Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development",
abstract = "We previously reported (Bell, D., P. Chomarat, D. Broyles, G. Netto, G.M. Harb, S. Lebecque, J. Valladeau, J. Davoust, K.A. Palucka, and J. Banchereau. 1999. J. Exp. Med. 190: 1417-1426) that breast cancer tumors are infiltrated with mature dendritic cells (DCs), which cluster with CD4+ T cells. We now show that CD4+ T cells infiltrating breast cancer tumors secrete type 1 (interferon γ) as well as high levels of type 2 (interleukin [IL] 4 and IL-13) cytokines. Immunofluorescence staining of tissue sections revealed intense IL-13 staining on breast cancer cells. The expression of phosphorylated signal transducer and activator of transcription 6 in breast cancer cells suggests that IL-13 actually delivers signals to cancer cells. To determine the link between breast cancer, DCs, and CD4+ T cells, we implanted human breast cancer cell lines in nonobese diabetic/LtSz-scid/scid β2 microglobulin-deficient mice engrafted with human CD34+ hematopoietic progenitor cells and autologous T cells. There, CD4+ T cells promote early tumor development. This is dependent on DCs and can be partially prevented by administration of IL-13 antagonists. Thus, breast cancer targets DCs to facilitate its development. JEM",
author = "Caroline Aspord and Alexander Pedroza-Gonzalez and Mike Gallegos and Sasha Tindle and Burton, {Elizabeth C.} and Dan Su and Florentina Marches and Jacques Banchereau and Palucka, {A. Karolina}",
year = "2007",
month = "5",
doi = "10.1084/jem.20061120",
language = "English (US)",
volume = "204",
pages = "1037--1047",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "5",

}

TY - JOUR

T1 - Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development

AU - Aspord, Caroline

AU - Pedroza-Gonzalez, Alexander

AU - Gallegos, Mike

AU - Tindle, Sasha

AU - Burton, Elizabeth C.

AU - Su, Dan

AU - Marches, Florentina

AU - Banchereau, Jacques

AU - Palucka, A. Karolina

PY - 2007/5

Y1 - 2007/5

N2 - We previously reported (Bell, D., P. Chomarat, D. Broyles, G. Netto, G.M. Harb, S. Lebecque, J. Valladeau, J. Davoust, K.A. Palucka, and J. Banchereau. 1999. J. Exp. Med. 190: 1417-1426) that breast cancer tumors are infiltrated with mature dendritic cells (DCs), which cluster with CD4+ T cells. We now show that CD4+ T cells infiltrating breast cancer tumors secrete type 1 (interferon γ) as well as high levels of type 2 (interleukin [IL] 4 and IL-13) cytokines. Immunofluorescence staining of tissue sections revealed intense IL-13 staining on breast cancer cells. The expression of phosphorylated signal transducer and activator of transcription 6 in breast cancer cells suggests that IL-13 actually delivers signals to cancer cells. To determine the link between breast cancer, DCs, and CD4+ T cells, we implanted human breast cancer cell lines in nonobese diabetic/LtSz-scid/scid β2 microglobulin-deficient mice engrafted with human CD34+ hematopoietic progenitor cells and autologous T cells. There, CD4+ T cells promote early tumor development. This is dependent on DCs and can be partially prevented by administration of IL-13 antagonists. Thus, breast cancer targets DCs to facilitate its development. JEM

AB - We previously reported (Bell, D., P. Chomarat, D. Broyles, G. Netto, G.M. Harb, S. Lebecque, J. Valladeau, J. Davoust, K.A. Palucka, and J. Banchereau. 1999. J. Exp. Med. 190: 1417-1426) that breast cancer tumors are infiltrated with mature dendritic cells (DCs), which cluster with CD4+ T cells. We now show that CD4+ T cells infiltrating breast cancer tumors secrete type 1 (interferon γ) as well as high levels of type 2 (interleukin [IL] 4 and IL-13) cytokines. Immunofluorescence staining of tissue sections revealed intense IL-13 staining on breast cancer cells. The expression of phosphorylated signal transducer and activator of transcription 6 in breast cancer cells suggests that IL-13 actually delivers signals to cancer cells. To determine the link between breast cancer, DCs, and CD4+ T cells, we implanted human breast cancer cell lines in nonobese diabetic/LtSz-scid/scid β2 microglobulin-deficient mice engrafted with human CD34+ hematopoietic progenitor cells and autologous T cells. There, CD4+ T cells promote early tumor development. This is dependent on DCs and can be partially prevented by administration of IL-13 antagonists. Thus, breast cancer targets DCs to facilitate its development. JEM

UR - http://www.scopus.com/inward/record.url?scp=34249000341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249000341&partnerID=8YFLogxK

U2 - 10.1084/jem.20061120

DO - 10.1084/jem.20061120

M3 - Article

C2 - 17438063

AN - SCOPUS:34249000341

VL - 204

SP - 1037

EP - 1047

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 5

ER -